Cannabinoid Derived Product is a Potential Novel Therapeutic for Papillary Thyroid Carcinoma

Abstract Rationale: Papillary thyroid carcinoma (PTC) is the most common thyroid cancer that typically affects women ages 20 to 50, presenting as an asymptomatic neck mass. Treatment with total or partial thyroidectomy shows an excellent prognosis. However, investigation of non-invasive therapeutic options with minimal adverse effects is ongoing. This study seeks to investigate the K1 cell line, which consists of PTC cells obtained from metastatic tumors of well-differentiated PTC. Objective: Our investigation focuses on a cannabinoid-based product (named BRF1-A) and